In addition to discrepancy on inhibitor dosages, a recent report showed there is a great deal of heterogeneousness among different tumor cell lines and even the same type of tumors, such as breast and prostate cancers in response to a Hsp90 inhibitor.40 The gene discussed is HSP90AA1; the disease is prostate carcinoma.